Anti-neovasculature preparations for cancer
AssigneeMannKind Corporation
InventorsJohn J. L. Simard, David C. Diamond
Life of this patent
Estimating the term…
Abstract
Disclosed herein are immunogenic compositions, methods of designing immunogenic compositions, methods of treatment using immunogenic compositions, methods of evaluating cell-mediated immunity resulting from immunogenic compositions, research models, and methods of making research models, all of which relate to targeting tumor vasculature.
Claims31
A method of treating neoplastic disease comprising the step of immunizing a mammal to induce a cellular immune response directed against an antigen differentially expressed by tumor-associated neovasculature, wherein the immunization comprises delivering a therapeutic nucleic acid vaccine, comprising at least one immunogen corresponding to an antigen expressed by tumor-associated neovasculature to a mammal having a neoplastic disease, wherein said antigen is vascular endothelial growth factor receptor 2 (VEGFR2).
A method of treating neoplastic disease comprising the step of immunizing a mammal to induce a cellular immune response directed against a first antigen differentially expressed by tumor-associated neovasculature and a second antigen associated with a tumor, wherein the immunization comprises delivering a therapeutic nucleic acid vaccine comprising at least a first immunogen corresponding to the first antigen and a second immunogen corresponding to the second antigen to a mammal having a neoplastic disease, wherein the first antigen is vascular endothelial growth factor receptor 2 (VEGFR2).
A method of treating neoplastic disease comprising the step of immunizing a mammal to induce a cellular immune response directed against an antigen differentially expressed by tumor-associated neovasculature, wherein the immunization comprises delivering a therapeutic nucleic acid vaccine comprising a first immunogen comprising at least one housekeeping epitope and a second immunogen comprising at least one immune epitope to a mammal having a neoplastic disease, wherein the housekeeping and immune epitopes are derived from said antigen differentially expressed by tumor-associated neovasculature, wherein the antigen is vascular endothelial growth factor receptor 2 (VEGFR2).
A method of treating neoplastic disease comprising the step of immunizing a mammal to induce a cellular immune response directed against an antigen differentially expressed by tumor-associated neovasculature, wherein the immunization comprises delivering a therapeutic nucleic acid vaccine comprising an immunogen comprising at least one housekeeping epitope derived from said antigen differentially expressed by tumor-associated neovasculature to a mammal having a neoplastic disease, wherein the antigen is vascular endothelial growth factor receptor 2 (VEGFR2).
Dependencies are inferred from the claim text.